** Shares of drugmaker Phathom Pharmaceuticals PHAT.O rise 134% to near 7-month high of $11
** Co's request to the US FDA to update the "Orange Book" has been approved, granting its stomach infection medication, Voquezna, a 10-year exclusivity period
** Stock set for its best day on record, if gains hold
** The exclusivity period will prevent other firms from making similar versions of Voquezna
** Phathom filed a citizen petition to the FDA last year, seeking this exclusivity
** This exclusivity was initially granted to other versions of the drug, Voquezna Paks, which contain the same active ingredient as Voquezna
** Exclusivity protection will extend through May 3, 2032
** Including session's moves, stock up 31% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。